Humanized Antibodies Against MFAP4 Epitopes
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current antibodies targeting Microfibrillar-associated protein 4 (MFAP4) are not efficient or reliable, and there is a need for improved antibodies with new binding properties to address vascular remodeling, angiogenesis, vascular leakage, and inflammation.
Innovation Solution
Development of novel humanized monoclonal antibodies with specific CDR sequences that bind to new epitopes of MFAP4, including light and heavy chain variable regions with unique amino acid compositions, providing enhanced stability and binding affinity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing antibodies targeting MFAP4 are used, then some binding activity is achieved, but the binding efficiency and reliability are insufficient
Solution Approach 1:
The patent applies parameter changes by modifying the antibody sequences to achieve superior binding characteristics. Specifically, the invention identifies and utilizes particular amino acid sequences in the CDR regions that confer enhanced binding affinity and reliability to MFAP4, representing a systematic optimization of the antibody parameters beyond conventional designs
Solution Approach 2:
The patent employs copying by creating humanized antibody versions (hAS0326) based on the murine antibody sequence (mAS0326). This involves copying the critical CDR sequences from the murine antibody while replacing framework regions with human sequences, thereby preserving the high-affinity binding properties while improving therapeutic applicability
2Reliability
If novel antibodies with new epitope binding are developed, then binding effectiveness is improved, but development complexity increases
Solution Approach 1:
The patent applies segmentation by dividing the antibody into functionally distinct regions with specific purposes. The CDR regions are identified as the critical segments for epitope recognition and binding, while framework regions provide structural support. This segmentation allows focused optimization of binding effectiveness in the CDR regions without compromising overall antibody stability
Solution Approach 2:
The patent demonstrates universality by designing antibodies that can bind to multiple epitopes on MFAP4 (differentiating between Type 1 and Type 2 epitopes). The humanized antibody format also provides multi-functionality by enabling both high-affinity binding and therapeutic applicability in human patients
Data Source
AI summary
The present invention relates to antibodies, including humanized antibodies that bind human Microfibrillar-associated protein 4 (MFAP4). The invention also relates to uses of such antibodies.